MEDIQ

Mediq, international supplier of medical devices and pharmaceuticals, has set the exchange ratio for the optional stock dividend for 2011.

Read more

Download PDF  (24 KB)

The Supervisory Committee of Mediq, international supplier of medical devices and pharmaceuticals, have re-appointed Hans Janssen Chief Financial Officer (CFO) as of 1 May 2012.

Read more

Download PDF  (101 KB)

Further growth of sales and result at Direct & Institutional

Financial highlights
Net sales
Up 1% to € 654.3 million due to growth at Direct & Institutional; decrease at Pharmacies Netherlands and Pharmacies Poland.

EBITA from ordinary activities
Down 10% to € 27.2 million due to decrease of € 4.4 million at Pharmacies Netherlands; EBITA at Direct & Institutional up 10%.

Net result
Down 21% to € 13.9 million due to lower EBITA and higher amortisation of customer relationships.

Net result per share from ordinary activities
Down 6% to € 0.30 due to lower EBITA from ordinary activities, partly compensated by a lower number of shares outstanding.

Cash flow
Cash flow from operating activities up significantly, to € 46.1 million, mainly due to improvement of working capital.

Outlook 2012
Where we previously expected a decrease of EBITA at Pharmacies Netherlands compared to 2011, we now expect that decrease to be substantial. The outlook for D&I and Pharmacies Poland is unchanged; at both segments we expect an increase in EBITA.


Read more

Download PDF  (372 KB)

Mediq, international supplier of medical devices and pharmaceuticals, announces that it is voluntarily joining Pensioenfonds Medewerkers Apotheken (PMA – Pharmacy Assistants’ Pension Fund) with immediate effect. To ensure the transfer proceeds successfully, Mediq will contribute a maximum amount of € 8.6 million in transition costs – including the compensation for missed indexation in prior years. In addition, Mediq will offer a compensation scheme enabling employees to adapt gradually to the new contribution over a five-year period, totalling € 1.4 million. The members of the trade unions FNV Bondgenoten and CNV Vakmensen have agreed to the transaction. The supervisory authority, the Dutch Central Bank DNB, has announced not to object to this collective transfer.

Read more

Download PDF  (45 KB)

Utrecht, 23 April 2012 – Mediq, international supplier of medical devices and pharmaceuticals, acquires Diabetes Specialty Centre (DSC). DSC delivers insulin pumps, continuous glucose monitors and the related supplies to frequent-user, insulin-dependent diabetics. Mediq has been active in the US through Byram Healthcare since 2008. This acquisition will consolidate Byram’s number 4 position in this large but fragmented market.

Read more

Download PDF  (29 KB)

Utrecht, 12 April 2012 – Yesterday the annual General Meeting of Shareholders of Mediq, has chosen to replace the current full statutory two-tier board regime by a mitigated two-tier board system.

Read more

Download PDF  (63 KB)

International Photo and Video Contest in the Run-up to World Diabetes Day

The 2012 edition of the World Diabetes Day Platform photo contest is being called “Diabetes in Focus.” Following the success of the 2010 and 2011 editions in the Netherlands and Germany, the campaign is also being held in the United States this year. Another exciting change is that the contest is open not only to photographers, but also to filmmakers – young and old, amateur and professional. The World Diabetes Day Platform organizes Diabetes 24/7 in conjunction with the international company Mediq. Through the photo competition, Mediq hopes to draw attention specifically to the plight of young people suffering from diabetes. Submissions will be accepted through October 1, 2012 at www.diabetes24-7.nl.

Read more

Download PDF  (142 KB)

Outlook 2011 realised

Financial highlights Q4 2011
Net sales
Up 3% to € 727.3 million due to acquisitions and organic growth at Direct & Institutional.

EBITA from ordinary activities
Up 16% to € 37.1 million mainly related to growth at Direct & Institutional; all segments reported growth.

Net result
Up 23% to € 22.8 million due to higher EBITA and lower finance costs.

Change in presentation revenues
of two Swedish distribution contracts with effect from 2011 Annual Report; see annexe 2 for more information.

Read more

Download PDF  (446 KB)